This article is more than 5 years old. Information may no longer be current.

FDA: SGLT2 inhibitors may increase bone fracture risk, decrease BMD

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The FDA recently warned that the medications Invokana and Invokamet may cause an increased risk for bone fractures.

It said, however, that patients should not change or stop their medications without talking to their physician. Health care providers of patients on Invokana (canagliflozin, Janssen) and Invokamet (canagliflozin, Janssen) should discontinue use of these SGLT2 inhibitors if appropriate.

The FDA is continuing to examine other drugs in the SGLT2 inhibitor class including Farxiga (dapagliflozin, AstraZeneca), Xigduo XR (dapagliflozin, AstraZeneca), Jardiance (empagliflozin, Boehringer Ingelheim), Glyxambi (empagliflozin/linagliptin, Boehringer Ingelheim) and Synjardy (empagliflozin/metformin, Boehringer Ingelheim) to determine if they also increase the risk for bone fractures.